USP30-IN-20

USP30-IN-20 (Compound 8m) shows potent anti-proliferative activity against PC3, DU145 prostate cancer cells, and CD24^-CD44⁺ prostate cancer stem-like cells, with IC₅₀ values of 4.87 μM, 5.44 μM, and 5.94 μM, respectively^[1].
USP30-IN-20 (2.5-5 μM, 14 days) significantly reduces the number of malignant colonies of PC3 and DU145 cells^[1].
USP30-IN-20 (2.5-5 μM, 24-48 h) induces G0/G1 phase arrest, inhibits the migration and suppresses the invasion capacity of PC3 and DU145 cells^[1].
USP30-IN-20 (2.5-5 μM, 72 h) disrupts tumor sphere formation and significantly reduces the number of spheroids in PC3 and DU145 cells^[1].
USP30-IN-20 (2.5-5 μM, 24 h) significantly upregulates intracellular ROS and lipid ROS levels, increases malondialdehyde (MDA) content and decreases glutathione (GSH) levels in PC3 and DU145 cells^[1].
USP30-IN-20 (5 μM, 24 h) causes mitochondrial shrinkage, disappearance of mitochondrial cristae and membrane structure, and disruption of mitochondrial membrane potential in PC3 cells, without affecting cell apoptosis^[1].
USP30-IN-20 (2.5-5 μM; 24 h) downregulates GPX4 protein expression in a dose-dependent manner in PC3 and DU145 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.